Using HIV Transmission Networks to Investigate Community Effects in HIV Prevention Trials

Effective population screening of HIV and prevention of HIV transmission are only part of the global fight against AIDS. Community-level effects, for example those aimed at thwarting future transmission, are potential outcomes of treatment and may be important in stemming the epidemic. However, current clinical trial designs are incapable of detecting a reduction in future transmission due to treatment. We took advantage of the fact that HIV is an evolving pathogen whose transmission network can be reconstructed using genetic sequence information to address this shortcoming. Here, we use an HIV transmission network inferred from recently infected men who have sex with men (MSM) in San Diego, California. We developed and tested a network-based statistic for measuring treatment effects using simulated clinical trials on our inferred transmission network. We explored the statistical power of this network-based statistic against conventional efficacy measures and find that when future transmission is reduced, the potential for increased statistical power can be realized. Furthermore, our simulations demonstrate that the network statistic is able to detect community-level effects (e.g., reduction in onward transmission) of HIV treatment in a clinical trial setting. This study demonstrates the potential utility of a network-based statistical metric when investigating HIV treatment options as a method to reduce onward transmission in a clinical trial setting.

[1]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[2]  M. Ciccozzi,et al.  HIV-1 subtype C transmission network: the phylogenetic reconstruction strongly supports the epidemiological data. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  A. Rambaut,et al.  Episodic Sexual Transmission of HIV Revealed by Molecular Phylodynamics , 2008, PLoS medicine.

[4]  M. Uhlén,et al.  Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[6]  Emmanuel Lagarde,et al.  Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.

[7]  Jeremy M. Brown,et al.  Source identification in two criminal cases using phylogenetic analysis of HIV-1 DNA sequences , 2010, Proceedings of the National Academy of Sciences.

[8]  Michael P Busch,et al.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.

[9]  David Dunn,et al.  Molecular Phylodynamics of the Heterosexual HIV Epidemic in the United Kingdom , 2009, PLoS pathogens.

[10]  David P. Mindell,et al.  Molecular evidence of HIV-1 transmission in a criminal case , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[12]  S. Vermund,et al.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.

[13]  Stephen Moses,et al.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial , 2007, The Lancet.

[14]  J. Mary,et al.  Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. , 2004, The New England journal of medicine.

[15]  Christopher Dye,et al.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model , 2009, The Lancet.

[16]  P. Lemey,et al.  Molecular testing of multiple HIV-1 transmissions in a criminal case , 2005, AIDS (London).

[17]  Connie Celum,et al.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis , 2010, The Lancet.

[18]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[19]  Christopher H Woelk,et al.  A public health model for the molecular surveillance of HIV transmission in San Diego, California , 2009, AIDS.

[20]  P. Lemey,et al.  Phylogenetic Reconstruction of a Known HIV-1 CRF04_cpx Transmission Network Using Maximum Likelihood and Bayesian Methods , 2004, Journal of Molecular Evolution.

[21]  K. Holmes,et al.  Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked? , 2005, The Journal of infectious diseases.

[22]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[23]  Oliver Laeyendecker,et al.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial , 2007, The Lancet.